You are here:

CJEU - T 471/13 / Judgment

Xellia Pharmaceuticals ApS and Alpharma, LLC, formerly Zoetis Products LLC v European Commission

Policy area:
Public Health
Deciding Body type:
Court of Justice of the European Union
Deciding Body:
General Court (Ninth Chamber)
Type:
Decision
Decision date:
08/09/2016

Key facts of the case:

APPLICATION for annulment in part of Commission Decision C(2013) 3803 final of 19 June 2013 relating to a proceeding under Article 101 [TFEU] and Article 53 of the EEA Agreement (Case AT.39226 — Lundbeck) and for reduction of the amount of the fine imposed on the applicants by that decision.

Competition — Agreements, decisions and concerted practices — Market for antidepressant medicinal products containing the active pharmaceutical ingredient citalopram — Concept of restriction of competition ‘by object’ — Potential competition — Generic medicinal products — Barriers to market entry resulting from the existence of patents — Agreement concluded between a patent holder and a generic undertaking — Duration of the Commission’s investigation - Rights of the defence — Fines — Legal certainty — Principle that penalties must have a proper legal basis)

Results (sanctions) and key consequences of the case:

...the General Court (Ninth Chamber) hereby:
1. Dismisses the action;
2. Orders Xellia Pharmaceuticals ApS and Alpharma LLC to pay the costs.